News

Æterna Zentaris has terminated its agreement with Sanofi-aventis US signed on March 5, 2009 for the development, commercialisation and licensing of cetrorelix in benign prostatic hyperplasia (BPH) for

Sanofi-aventis and Chattem have entered into an agreement under which sanofi-aventis is to acquire Chattem for approximately $1.9 billion. Sanofi-aventis also announced that it will seek to convert

The Procter & Gamble (P&G) has voluntarily recalled its Vicks DayQuil Cold & Flu 24-Count LiquiCaps Bonus Pack in the US. P&G said it is taking this action

ZymoGenetics has reported a restructuring of the US co-promotion and ex-US license and collaboration agreements with Bayer Schering Pharma and Bayer HealthCare relating to Recothrom Thrombin, topical (Recombinant).

Sanofi-aventis has provided an update of its R&D pipeline for four of its projects: DuoPlavin in cardiology, Cabazitaxel in oncology, Eplivanserin in insomnia and Idrabiotaparinux in thrombosis. On

AkzoNobel will start the production at its chelates facility located at the company’s new E275m multi-site in Ningbo, China, this week. The company now claims itself to be

Clinuvel Pharmaceuticals has obtained positive 4-months results in testing Afamelanotide in a multicentre randomised double-blind placebo controlled Phase III study in EPP (CUV017). In 2008, Afamelanotide was awarded

Agios Pharmaceuticals (Agios) has received funding from Accelerate Brain Cancer Cure (ABC2). ABC2’s funding will enable new research investigating IDH1 gene mutations in brain cancer, with the goal

Unilife Medical Solutions (Unilife) has commenced final preparations for the commercial release and sale of its Unitract 1ml syringes, following the completion of device ageing studies for product